Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Sinéad Delany‐Moretlwe, James P. Hughes, Peter Bock, et al.
The Lancet (2022) Vol. 399, Iss. 10337, pp. 1779-1789
Open Access | Times Cited: 359

Showing 1-25 of 359 citing articles:

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Rajesh T. Gandhi, Roger Bedimo, Jennifer Hoy, et al.
JAMA (2022) Vol. 329, Iss. 1, pp. 63-63
Closed Access | Times Cited: 375
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Linda‐Gail Bekker, Moupali Das, Quarraisha Abdool Karim, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 13, pp. 1179-1192
Closed Access | Times Cited: 137
HIV infection
Linda‐Gail Bekker, Chris Beyrer, Nyaradzo Mgodi, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Closed Access | Times Cited: 101
Prevention, treatment and cure of HIV infection
Raphael J. Landovitz, Hyman Scott, Steven G. Deeks
Nature Reviews Microbiology (2023) Vol. 21, Iss. 10, pp. 657-670
Closed Access | Times Cited: 79
A Look at the Importance of Chirality in Drug Activity: Some Significative Examples
Jessica Ceramella, Domenico Iacopetta, Angelica Franchini, et al.
Applied Sciences (2022) Vol. 12, Iss. 21, pp. 10909-10909
Open Access | Times Cited: 76
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 31
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women
Jeanne Marrazzo, Tao Li, Marissa Becker, et al.
JAMA (2024) Vol. 331, Iss. 11, pp. 930-930
Open Access | Times Cited: 27
Antiretrovirals and Weight Change: Weighing the Evidence
David A. Wohl, John R. Koethe, Paul E. Sax, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. 999-1005
Closed Access | Times Cited: 18
Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084
Sinéad Delany‐Moretlwe, Brett Hanscom, Xu Guo, et al.
Journal of the International AIDS Society (2025) Vol. 28, Iss. 1
Open Access | Times Cited: 2
Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South
Dylan Baker, Lauren F. Collins, Valeria D. Cantos, et al.
Journal of General Internal Medicine (2025)
Closed Access | Times Cited: 2
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study
Vamshi Jogiraju, P. S. Pawar, Jenna Yager, et al.
The Lancet (2025)
Closed Access | Times Cited: 2
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
Alexa Zhao, Rustin D. Crutchley, Rakesh Guduru, et al.
Retrovirology (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 63
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
Jennifer Smith, Loveleen Bansi‐Matharu, Valentina Cambiano, et al.
The Lancet HIV (2023) Vol. 10, Iss. 4, pp. e254-e265
Open Access | Times Cited: 41
Preexposure Prophylaxis to Prevent Acquisition of HIV
Michael J. Barry, Wanda K. Nicholson, Michael Silverstein, et al.
JAMA (2023) Vol. 330, Iss. 8, pp. 736-736
Open Access | Times Cited: 35
HIV epidemiology, prevention, treatment, and implementation strategies for public health
Aaloke Mody, Annette H. Sohn, Collins Iwuji, et al.
The Lancet (2023) Vol. 403, Iss. 10425, pp. 471-492
Closed Access | Times Cited: 35
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
Raphael J. Landovitz, Brett Hanscom, Meredith E. Clement, et al.
The Lancet HIV (2023) Vol. 10, Iss. 12, pp. e767-e778
Open Access | Times Cited: 32
Systematic review of the values and preferences regarding the use of injectable pre‐exposure prophylaxis to prevent HIV acquisition
Lara Lorenzetti, Nhi Dinh, Ariane van der Straten, et al.
Journal of the International AIDS Society (2023) Vol. 26, Iss. S2
Open Access | Times Cited: 30
Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe
Deniz Gökengin, Teymur Noori, Andrea Alemany, et al.
The Lancet Regional Health - Europe (2023) Vol. 34, pp. 100738-100738
Open Access | Times Cited: 30
Preexposure Prophylaxis for the Prevention of HIV
Roger Chou, Hunter Spencer, Christina Bougatsos, et al.
JAMA (2023) Vol. 330, Iss. 8, pp. 746-746
Open Access | Times Cited: 28
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities
Jessica E. Haberer, Andrew Mujugira, Kenneth H. Mayer
The Lancet HIV (2023) Vol. 10, Iss. 6, pp. e404-e411
Closed Access | Times Cited: 27
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Mohammad Ullah Nayan, Brady Sillman, Mahmudul Hasan, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 115009-115009
Open Access | Times Cited: 26
Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
Virginia A. Fonner, Kathleen Ridgeway, Ariane van der Straten, et al.
AIDS (2023) Vol. 37, Iss. 6, pp. 957-966
Open Access | Times Cited: 24
Preferences and acceptability for long‐acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya
Nafisa J. Wara, Rufaro Mvududu, Mary M. Marwa, et al.
Journal of the International AIDS Society (2023) Vol. 26, Iss. 5
Open Access | Times Cited: 24
Updating the Adherence–Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women
Peter L. Anderson, Mark A. Marzinke, David V. Glidden
Clinical Infectious Diseases (2023) Vol. 76, Iss. 10, pp. 1850-1853
Closed Access | Times Cited: 23
Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment and Prevention for People Experiencing Homelessness
Nicky J. Mehtani, Alix Strough, Sarah Strieff, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2024) Vol. 96, Iss. 1, pp. 61-67
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top